chronic lymphocytic leukemia

Type: Keyphrase
Name: chronic lymphocytic leukemia
First reported Oct 20 2014 - Updated 17 hours ago - 1 reports

Pharmacyclics' Imbruvica gets European approval to treat two blood cancers

The European Commission (EC) has granted marketing approval for Pharmacyclics' Imbruvica (ibrutinib), a first-in-class, oral, once-daily, non-chemotherapy treatment for patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients ... [Published PBR - News - Oct 20 2014]
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Promise Put to the Test

UC San Diego Sanford Stem Cell Clinical Center is pushing therapeutic stem cell-based science out of the laboratory and closer to real-world medical applications. The unprecedented trials involve potential therapies for spinal cord injuries, Type 1 diabetes ... [Published Infrosoft - 18 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Harnessing the Power of Modified T Cells to Treat Cancer

New data from the University of Pennsylvania and The Children’s Hospital of Philadelphia reveal that an immunotherapy, named CTL019, helped 90% of children and adults with acute lymphoblastic leukemia (ALL) who had failed to respond to prior treatments ... [Published PharmTech.com - 20 hours ago]
First reported Oct 17 2014 - Updated Oct 18 2014 - 1 reports

Sector Update: Health Care

The drug was approved for adult patients with relapsed or refractory mantle cell lymphoma, or adult patients with chronic lymphocytic leukemia.Shares in the company were trading 5.34% higher at $114.97 during pre-market trading . Over the past 52 weeks, ... [Published Nasdaq - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 17 2014 - 3 reports

Pharmacyclics and Roche research Imbruvica and Gazyva

USA-based biopharma company Pharmacyclics (Nasdaq: PCYC) has entered into a master clinical drug supply agreement with Swiss drug major Roche (ROG: SIX) to evaluate the safety, tolerability and preliminary efficacy of Imbruvica (ibrutinib) in combination ... [Published Pharma Letter - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Roche Reports Strong Sales Results for 9 Months of 2014

Roche ( RHHBY ), a leader in oncology drugs, reported encouraging sales results for the first nine months of 2014.Sales increased 5% from the year-ago period, driven by growth in both its segments – Pharmaceuticals Division and Diagnostics Division. Revenues ... [Published Yahoo! Finance - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Five things for pharma marketers to know: Thursday, October 16

Share this article: Five things for pharma marketers to know: Thursday, October 16AbbVie board recommends against Shire deal; consultancy says Netherland's generic bias hampers branded drug sales; Genentech and BI score FDA approval for fatal lung di ... [Published Medical Marketing And Media - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Bristol-Myers Squibb, Pharmacyclics and Janssen collaborate

Bristol-Myers Squibb ,  Pharmacyclics and  Janssen R&D have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of BMS’ investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) ... [Published Center Watch - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

BMS Pharmacyclics and Janssen collaborate on cancer

The Phase I/II study conducted by Janssen will evaluate the safety and efficacy of the combined drugs for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia ... [Published BioPortfolio - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Five things for pharma marketers to know: Tuesday, October 14

Share this article: Bristol-Myers Squibb, Pharmacyclics and J&J's Janssen announced a collaboration under which they will test the tolerability and effectiveness of a combination of Opdivo (nivolumab) and Imbruvica (ibrutinib) in non-Hodgkin lymphoma, ... [Published Medical Marketing And Media - Oct 14 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 2 reports

FDA's Decision On Imbruvica Will Push Pharmacyclics Higher

By Mix Star :Background:Related Biotechnology, Pharmaceutical and Healthcare NewsThe FDA decision on Pharmacyclics' (NASDAQ: PCYC ) IMBRUVICA, for a full approval of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma , will push ... [Published BioPortfolio - Sep 29 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 3 reports

Gilead’s Zydelig And Johnson and Johnson-Pharmacyclic’s Imbruvica Fighting To Lead Anti-Cancer Drug Race

Gilead and J&J are going head-to-head with their drugs Zydelig and Imbruvica, used to treat various indications related to cancer. Despite Gilead‘s lower pricing it still needs to cope with black box warnings associated with ZydeligPage 1 of 3Click Ticker ... [Published Bidness Etc - Sep 22 2014]

Quotes

...that Imbruvica may provide through a variety of uses across several hematologic malignancies," said Bob Duggan, Chairman & CEO, Pharmacyclics. "We look forward to a rewarding and productive partnership with Roche to evaluate our product with GAZYVA in order to deliver new treatment options to patients with NHL and CLL."
"With the advent of new therapies, our patients are living longer, but after time, patients may stop responding or may develop resistance to the drug, hence the need to get new agents approved,” Jacqueline C Barrientos, MD, an assistant professor at Hofstra North Shore-LIJ School of Medicine in New York, explained in an interview. "As a physician treating mainly hard-to-treat refractory cases, we need these new agents to salvage our patients after each relapse. CLL is a chronic condition and there is no cure for our patients.""
"What we are seeing after years of work is the rubber hitting the road" said Lawrence Goldstein, director of the UC San Diego Stem Cell program and Sanford Stem Cell Clinical Center
Pharmacyclics CEO Bob Duggan said: "We are very pleased that patients with CLL and relapsed or refractory MCL in the European Union will have a first-in-class, oral, single-agent, non-chemotherapy treatment option in Imbruvica."

More Content

All (311) | News (247) | Reports (0) | Blogs (52) | Audio/Video (0) | Fact Sheets (1) | Press Releases (10)
sort by: Date | Relevance
Pharmacyclics Signs Agreement with Roche [Published Individual.com - 7 hours ago]
NBIX For The Long Haul, RegeneRx Catches Invest... [Published RTTNews.com - 10 hours ago]
Oral Therapies Shift Treatment Paradigm in CLL [Published OncLive - 18 hours ago]
UC San Diego Health System announces human test... [Published San Diego 6 - 18 hours ago]
Promise Put to the Test [Published Infrosoft - 18 hours ago]
Promise Put to the Test [Published Newswise - 19 hours ago]
Pharmacyclics, Roche Enter Clinical Drug Supply... [Published Contract Pharma - 20 hours ago]
Harnessing the Power of Modified T Cells to Tre... [Published PharmTech.com - 20 hours ago]
Pharmacyclics files Imbruvica sNDA for Waldenst... [Published Pharma Letter - 21 hours ago]
Pharmacyclics’ Imbruvica receives European appr... [Published Pharmaceutical Technology - 22 hours ago]
Celgene Corp. invests in biotech firm Sequenta [Published PE Hub Blog - 22 hours ago]
New Strategies Emerge for Managing CLL Patients... [Published OncLive - 23 hours ago]
Baxter Launches HYQVIA in the United States for... [Published Investor's Business Daily - Oct 20 2014]
Baxter Launches HYQVIA in the United States for... [Published Nasdaq - Oct 20 2014]
Biogen Expected To Report Positive Q3 Earnings [Published Bidness Etc - Oct 20 2014]
Pharmacyclics Files Supplemental New Drug Appli... [Published Pettinga Financial Advisors - Oct 20 2014]
Pharmacyclics receives European Commission's m... [Published Individual.com - Oct 20 2014]
Pharmacyclics' Imbruvica gets European approval... [Published PBR - News - Oct 20 2014]
Livestrong CEO Doug Ulman Leaving to Head Pelot... [Published Oncology Times - Oct 19 2014]
Pharmacyclics, Roche Ink Deal for Cancer Combo ... [Published Zacks.com - Oct 17 2014]
Five things for pharma marketers to know: Frida... [Published Medical Marketing And Media - Oct 17 2014]
Pharmacyclics' Non-Chemo Treatment Approved in ... [Published Drug Discovery and Development - Oct 17 2014]
Pharmacyclics’ Imbruvica gains EU approval for ... [Published Pharma Letter - Oct 17 2014]
Sector Update: Health Care [Published Nasdaq - Oct 17 2014]
Roche Reports Strong Sales Results for 9 Months... [Published Yahoo! Finance - Oct 17 2014]
IMBRUVICA(R) (ibrutinib) Now Approved in Europe... [Published Scottrade - Oct 17 2014]
Pharmacyclics and Roche research Imbruvica and ... [Published Pharma Letter - Oct 17 2014]
Recent Purchase: Johnson & Johnson [Published Seeking Alpha - Oct 17 2014]
AFFX In Harmony, SRPT, IBIO Focusing On Ebola, ... [Published RTTNews.com - Oct 17 2014]
Review of Selected NMEs 2014 [Published U.S.Pharmacist - Oct 16 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Celgene Corp. invests in biotech firm Sequenta [Published PE Hub Blog - 22 hours ago]
South San Francisco-base biotech firm Sequenta has received undisclosed funding from Celgene Corp. and various unnamed investors. Sequena is also backed by Foresite Capital Management, Mohr Davidow Ventures and Index Ventures . PRESS RELEASE ...
Pharmacyclics' Imbruvica gets European approval... [Published PBR - News - Oct 20 2014]
The European Commission (EC) has granted marketing approval for Pharmacyclics' Imbruvica (ibrutinib), a first-in-class, oral, once-daily, non-chemotherapy treatment for patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients ...
NEA adds new partner to team [Published PE Hub Blog - Oct 09 2014]
New Enterprise Associates has hired Dr. Carol Gallagher as a partner at its Menlo Park office. Previously, she was the chairman of eFFECTOR Therapeutics , a director at Aragon Pharmaceuticals (which was bought by Johnson & Johnson in 2013) and ...
Gilead’s cancer drug Zydelig gets European mark... [Published PBR - News - Sep 22 2014]
Gilead Sciences has secured marketing authorization from the European Commission for its Zydelig (idelalisib) 150mg tablets to treat two incurable blood cancers, chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). ...
European Commission Grants Marketing Authorizat... [Published Business Wire Health News - Sep 19 2014]
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
TG Therapeutics Announces Special Protocol Asse... [Published GlobeNewswire: Acquisitions News - Sep 15 2014]
TG Therapeutics Announces Novel "Chemo-free" Tr... [Published GlobeNewswire: Earnings News - Aug 15 2014]
TG Therapeutics' Novel Combination of TG-1101 (... [Published GlobeNewswire: Advertising News - Jul 21 2014]
GSK and Genmab Receive EU Authorization for Arz... [Published GlobeNewswire: Nutrition News - Jul 03 2014]
TG Therapeutics Completes Global Licensing Agre... [Published GlobeNewswire: Advertising News - Jun 24 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.